Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects
Sponsor: Theracos
Listed as NCT03167411, this PHASE1 trial focuses on Type2 Diabetes Mellitus and remains completed. Sponsored by Theracos, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theracos
For direct contact, visit the study record on ClinicalTrials.gov .